Skip to main content
. 2015 Aug 4;30(3):352–360. doi: 10.3803/EnM.2015.30.3.352

Table 4. Hierarchical Multiple Regression Analysis between Indices of Glycemic Variability and Other Variables.

Variable Standard deviation Mean absolute glucose change
Model 1
(R2 =0.185)		 Model 2
(R2 =0.242)		 Model 3
(R2 =0.235)		 Model 1
(R2 =0.116)		 Model 2
(R2 =0.195)		 Model 3
(R2 =0.179)
β P value β P value β P value β P value β P value β P value
Age, yr 0.040 0.540 0.068 0.290 0.057 0.400 0.024 0.731 0.057 0.405 0.060 0.403
Male sex 0.031 0.639 0.004 0.950 0.005 0.946 0.121 0.086 0.083 0.225 0.100 0.181
HbA1c, mmol/mol 0.325 <0.001 0.288 <0.001 0.264 <0.001 0.236 0.001 0.192 0.007 0.190 0.013
Duration of diabetes, yr 0.152 0.024 0.088 0.209 0.107 0.158 0.100 0.161 0.026 0.722 0.072 0.366
Frequency of hypoglycemia 0.233 <0.001 0.189 0.004 0.205 0.002 0.209 0.003 0.162 0.017 0.158 0.024
C-peptide, nmol/L 0.151 0.024 0.087 0.193 0.106 0.174 0.160 0.024 0.093 0.183 0.109 0.183
Use of SUa - - 0.231 0.003 0.209 0.009 - - 0.248 0.002 0.214 0.011
Use of DPP4ia - - -0.096 0.168 -0.114 0.113 - - -0.135 0.066 -0.144 0.059
Use of AGIa - - -0.142 0.024 -0.111 0.095 - - -0.144 0.030 -0.128 0.067
Use of METa - - 0.051 0.417 0.042 0.522 - - 0.071 0.280 0.061 0.376
Use of TZDa - - -0.050 0.443 -0.072 0.296 - - -0.037 0.581 -0.039 0.586
UACR, mg/g - - - - 0.046 0.489 - - - - -0.085 0.229
Waist circumference, cm - - - - 0.074 0.347 - - - - 0.037 0.659
LDL-C, mmol/L - - - - -0.108 0.112 - - - - -0.074 0.295
HDL-C, mmol/L - - - - -0.009 0.903 - - - - 0.024 0.747
Triglyceride, mmol/L - - - - -0.011 0.891 - - - - 0.036 0.651
hsCRP, mmol/L - - - - -0.059 0.380 - - - - -0.083 0.243
Uric acid, µmol/L - - - - -0.059 0.435 - - - - 0.020 0.799

R2, adjusted R squared; β, corrected regression coefficient; HbA1c, glycated hemoglobin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; MET, metformin; TZD, thiazolidinedione; UACR, urine albumin:creatinine ratio; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein.

aThe use of individual oral hypoglycemic agent was defined as whether or not taking the medication regardless of combination therapy.